BENITEC BIOPHARMA INC (BNTC)

Company Profile

Benitec Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Hayward, California and currently employs 18 full-time employees. The company went IPO on 2012-07-11. Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The firm is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The firm's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).

Company Info

BENITEC BIOPHARMA INC

3940 Trust Way

Hayward CALIFORNIA 94545

P: 15107800819

CEO: Jerel Banks

Employees: 18

Website: https://benitec.com/